In the latest session, ImmunoGen Inc. (NASDAQ: IMGN) closed at $5.29 down -0.56% from its previous closing price of $5.32. In other words, the price has decreased by -$0.03 from its previous closing price. On the day, 3297191 shares were traded. IMGN stock price reached its highest trading level at $5.35 during the session, while it also had its lowest trading level at $5.14.
For a deeper understanding of ImmunoGen Inc.’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.20 and its Current Ratio is at 3.20. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Truist on November 21, 2022, initiated with a Buy rating and assigned the stock a target price of $10.
On September 09, 2022, Barclays started tracking the stock assigning a Overweight rating and target price of $8.
RBC Capital Mkts Downgraded its Outperform to Sector Perform on March 21, 2022, whereas the target price for the stock was revised from $9 to $6.
For the stock, the TTM Price-to-Sale (P/S) ratio is 12.05 while its Price-to-Book (P/B) ratio in mrq is 7.56.
Stock Price History:
Over the past 52 weeks, IMGN has reached a high of $7.77, while it has fallen to a 52-week low of $3.10. The 50-Day Moving Average of the stock is 5.48, while the 200-Day Moving Average is calculated to be 5.04.
For the past three months, IMGN has traded an average of 3.64M shares per day and 5.87M over the past ten days. A total of 253.51M shares are outstanding, with a floating share count of 219.87M. Insiders hold about 0.30% of the company’s shares, while institutions hold 92.70% stake in the company. Shares short for IMGN as of Oct 13, 2022 were 14.66M with a Short Ratio of 17.72M, compared to 12.14M on Sep 14, 2022. Therefore, it implies a Short% of Shares Outstanding of 6.64% and a Short% of Float of 6.67%.
There are 11 different market analysts currently analyzing its stock. On average, analysts expect EPS of -$0.25 for the current quarter, with a high estimate of -$0.23 and a low estimate of -$0.3, while EPS last year was -$0.18. The consensus estimate for the next quarter is -$0.25, with high estimates of -$0.23 and low estimates of -$0.27.
Analysts are recommending an EPS of between -$0.81 and -$1.04 for the fiscal current year, implying an average EPS of -$0.86. EPS for the following year is -$0.84, with 11 analysts recommending between -$0.61 and -$1.05.
A total of 11 analysts believe the company’s revenue will be $12.48M this quarter.It ranges from a high estimate of $15M to a low estimate of $7M. As of the current estimate, ImmunoGen Inc.’s year-ago sales were $9.21M, an estimated increase of 35.50% from the year-ago figure. For the next quarter, 10 analysts are estimating revenue of $15.68M, a decrease of -44.00% less than the figure of $35.50% in the same quarter last year. There is a high estimate of $25.7M for the next quarter, whereas the lowest estimate is $10.16M.
A total of 11 analysts have provided revenue estimates for IMGN’s current fiscal year. The highest revenue estimate was $89.35M, while the lowest revenue estimate was $75.08M, resulting in an average revenue estimate of $80.22M. In the same quarter a year ago, actual revenue was $69.86M, up 14.80% from the average estimate. Based on 11 analysts’ estimates, the company’s revenue will be $119.77M in the next fiscal year. The high estimate is $246.83M and the low estimate is $57.7M. The average revenue growth estimate for next year is up 49.30% from the average revenue estimate for this year.